SEAGEN

📅 Upcoming

🕒 Recent(90d)

News

• Pfizer punts Seagen ADC, further muddying value of the $43B buyout
  The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…
  biospace · 15d ago
• Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
  Plus, news about Novartis. 🤝 Pfizer turns over ADC: The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known as PF-08046031, a Seagen-de…
  endpoints · 16d ago
• Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
  Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier this year.
  fiercebiotech · 16d ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 1mo ago
• Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
  Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
  biospace · 1mo ago
• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 1mo ago
• Make or break: Commercial hires critical for success
  With the stakes for successful launches high, and demand for commercial roles increasing, biopharmas must thoughtfully approach not only hiring but also retention. During a BioSpace webinar, experi…
  biospace · 1mo ago
• Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
  This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…
  biospace · 1mo ago
• Merck ADC, in China study, shows potential to replace chemo in lung cancer
  The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
  biopharma_dive · 2mo ago
• Pfizer CFO to step down; Denali sells a regulatory fast-pass
  A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid divid…
  biopharma_dive · 3mo ago